clinical trial · NCT06507839
Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268
Thryv Therapeutics, Inc.·phase1·completed·n = 56
Atrial FibrillationTHRV-1268Placebo
brief summary
This is a single-center, randomized, double-blind, placebo-controlled study to be conducted in 2 parts: single ascending dose (SAD) incorporating a food effect arm and multiple ascending dose (MAD). Potential participants for each part will undergo screening procedures within 28 days of enrollment.
started
May 15, 2024
primary completion
Nov 1, 2024
completion
Nov 1, 2024
last updated
May 13, 2025
official title
A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study To Assess the Safety, Tolerability, Pharmacokinetics, and Food Effect of Thrv-1268 in Healthy Adult Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol